MRNA

Moderna, Inc. Common Stock · XNAS · 131 sessions on record

Health Care

$192.57▼ −10.89 · −5.3%from $203.46 the session before · Sep 30, 2026 close · end of day

Open: $186.55
High: $196.83
Low: $184.58
Day's range: $126.0% of the previous close
VWAP: $190.41close +1.1% from it
Volume, shares: 20.6M1.37× the 20-session average
Traded, $: $3.93B
Trades: 286K72 shares per trade
Previous close: $203.46−10.89 to the close
Market cap: $76.88Bat the close of Sep 30

Day range65% of the way up

$184.58$196.83

52-week range90% of the way up

$43.68 May 1$208.90 Sep 29

−7.8% from the high · +340% from the low

The desk read · Sep 30expiry Oct 16 · 16 days

put-heavy

options read

calls 43% · puts 57% of OI

1.32

puts per call, by OI

Oct 16 expiry 1.35

$150.00

max pain

−22% from the close

$200.00

most call OI

4.47K contracts · +3.9% from the close

▲ +2.6%

option OI on the day

+20.8K contracts · 836K open

Put-heavy into a 16-day expiry: 1.32 puts per call by open interest, option OI +2.6% on the day, the most call OI sits at $200.00, the most put OI at $120.00, max pain $150.00.

Options

Sep 30 open interest · 17 expiries listed

MRNA options carry 836K contracts of open interest across 17 expiries, 12% of it in the Oct 16 contract, with 1.32 puts per call.

Open interest by expirythe next 8 of 17 expiries · share of all open interest

Option open interest by expiry, the next 8 expiries
Expiry	Call OI · on the day	Put OI · on the day	Puts per call	Share of OI %	Strikes
Oct 22 days	51.5K+1.65K	39.4K+3.9K	0.77	11	122
Oct 99 days	10.3K+1.08K	9.37K+1.83K	0.91	2.4	81
Oct 1616 days	43.2K+1.77K	58.4K+3.78K	1.35	12	74
Oct 2323 days	7.43K+1K	7K+128	0.94	1.7	70
Oct 3030 days	8.32K+218	5.43K+334	0.65	1.6	70
Nov 637 days	1.38K+435	519+138	0.38	0.23	43
Nov 2051 days	37.3K+1.14K	55.8K+1.28K	1.50	11	44
Dec 1879 days	56.5K+164	69K+288	1.22	15	55

75% of open interest sits beyond the Oct 16 contract · 74 strikes listed for it · 836K contracts open in all

Monthly contractOct 16 expiry · 16 days

The Oct 16 contract holds 43.2K calls and 58.4K puts, the most call OI at $200.00 and the most put OI at $120.00; max pain $150.00, −22% from the close.

Call OI, contracts: 43.2K+1.77K on the day
Put OI, contracts: 58.4K+3.78K on the day
Puts per call, by OI: 1.35all expiries 1.32
Max pain: $150.00−22% from the close
Strikes listed: 74for this expiry

Open interest by strike, contractstop three strikes each side

Calls

Strike

Puts

4.47K

$200.00

3.02K

$180.00

2.86K

$165.00

$120.00

5.58K

$55.00

3.09K

$40.00

3.38K

Open interest added on the day, contractsthree largest additions each side

Calls

Strike

Puts

+219

$210.00

+132

$207.50

$202.50

+454

+923

$200.00

$180.00

+876

$150.00

+440

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it

131 sessions on file · from Mar 25

MRNA close
S&P 500, rebased

Session read · latest close: Sep 30, 2026
Close $ · day %: $192.57▼ −5.4% on the previous close
Against S&P 500: S&P 500 −0.2%−5.1 pp difference on the day
Against the averages: above 20 · above 5020-session $163.73 (+18%) · 50-session $118.36 (+63%)
Volume: 1.37×the previous 20 sessions · 20.6M shares
Extremes on the day: none

Quarterly results

consolidated · latest filed Jul 31, 2026 · SEC filings

Revenue $145.0M, +2.1% on a year earlier; profit −$782.0M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session

Quarterly results of MRNA on the consolidated basis with the market's move on the first session after each filing
Quarter	Revenue $	Revenue YoY	Profit $	Profit YoY	EPS $	Market on the day
Jun 2026filed Jul 31	$145.0M	▲ +2.1%	−$782.0M	—	-1.97	▲ +0.6%S&P 500 +1.4% · −0.8 pp
Mar 2026filed May 1	$389.0M	▲ +260%	−$1.34B	—	-3.40	▲ +4.3%S&P 500 −0.4% · +4.6 pp
Dec 2025filed Feb 20	$678.0M	▼ −30%	−$826.0M	—	-2.10	—not reached
Sep 2025filed Nov 6	$1.02B	▼ −45%	−$200.0M	▼ −1,600%	-0.51	—not reached
Jun 2025filed Jul 31	$142.0M	▼ −41%	−$825.0M	—	-2.13	▲ +0.6%S&P 500 +1.4% · −0.8 pp
Mar 2025filed May 1	$108.0M	▼ −35%	−$971.0M	—	-2.52	▲ +4.3%S&P 500 −0.4% · +4.6 pp
Dec 2024filed Feb 21	$966.0M	▼ −66%	−$1.12B	▼ −620%	-2.91	—not reached
Sep 2024filed Nov 6	$1.86B	▲ +1.7%	$13.0M	—	0.03	—not reached

By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends

Financial-year results of MRNA on the consolidated basis, summed from the quarters filed
Year	Revenue $	Revenue YoY	Profit $	Profit YoY	EPS $
FY25to Dec 2025	$1.94B	▼ −40%	−$2.82B	—	-7.26
FY24to Dec 2024	$3.24B	▼ −53%	−$3.56B	—	-9.28
FY23to Dec 2023	$6.85B	▼ −64%	−$4.71B	▼ −160%	-12.33
FY22to Dec 2022	$19.26B	▲ +4.3%	$8.36B	▼ −31%	20.12
FY21to Dec 2021	$18.47B	▲ +2,200%	$12.20B	—	28.29

Fundamentals

consolidated · filings to Jun 2026 · close $192.57 on Sep 30

11 times book value, revenue −28% over twelve months, market cap $76.88B.

Valuation

Market cap: $76.88Bon Sep 30
Price to earnings: —
Trailing EPS: $-7.98diluted · consolidated · four quarters to Jun 2026
Price to book: 11consolidated · balance sheet to Jun 2026
Book value a share: $16.93consolidated · balance sheet to Jun 2026
Debt to equity: —
Return on equity: -39%trailing profit over average equity · consolidated
Dividend yield: —
Price to sales: 35market cap over revenue, four quarters to Jun 2026
Shares outstanding: 399Mon Sep 30

Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated

Revenue, trailing 12 months: $2.23Bfour quarters to Jun 2026
Revenue growth, 12 months: ▼ −28%against the twelve months before
Revenue 3-year CAGR: ▼ −41%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months: −$3.15Bfour quarters to Jun 2026
Profit growth, 12 months: —
Profit 3-year CAGR: —

PeersBiological Products, (No Diagnostic Substances) · the ten largest by market cap · industry P/E needs two stocks with trailing profit and a market cap

Stocks in the industry Biological Products, (No Diagnostic Substances) with market cap, price to earnings and price to book
Stock	Market cap	P/E	P/B	Close $
MRNAModerna, Inc. Common Stock	$76.88Bon Sep 30	—	11	$192.57
HALOHalozyme Therapeutics, Inc.	$12.53Bon Sep 30	32consolidated	87	$110.40
TECHBio-Techne Corp.	$11.36Bon Sep 30	62consolidated	5.4	$72.47
KODKodiak Sciences Inc Common Stock	$5.96Bon Sep 30	—	98	$94.80
ALLOAllogene Therapeutics, Inc. Common Stock	$552.8Mon Sep 30	—	1.3	$1.60
DTILPrecision BioSciences, Inc. Common Stock	$172.8Mon Sep 30	—	3.8	$6.26
OTLKOutlook Therapeutics, Inc. Common Stock	$139.6Mon Sep 30	—	—	$0.57
BSEMBioStem Technologies, Inc. Common Stock	$55.2Mon Sep 30	—	2.0	$3.09
TVGNTevogen Inc. Common Stock	$43.1Mon Sep 30	—	—	$6.62
BCDABioCardia, Inc. Common Stock	$15.3Mon Sep 30	—	5.7	$1.01

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 160% of shares, FMR LLC the largest at 26%, BlackRock, Inc. 15% and VANGUARD CAPITAL MANAGEMENT LLC 12%, as filed for the quarter to Jun 2026.

26.0%15.3%11.6%105.1%

Held by 13F managers: 160%of shares outstanding
Shares held: 631M+1.1% on Mar 2026 among managers filing both
Managers holding: 732673 a quarter earlier
Largest holder: 26%FMR LLC

Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter

Largest 13F holders of MRNA
Manager	Shares	Of outstanding	Value	Change on quarter
FMR LLC	104M	26%	$7.26B	+12.4M
BlackRock, Inc.	61.2M	15%	$4.29B	+1.93M
VANGUARD CAPITAL MANAGEMENT LLC	46.4M	12%	$3.25B	+673K
Capital World Investors	44.6M	11%	$3.12B	+7.16M
BAILLIE GIFFORD & CO	36.4M	9.1%	$2.55B	−3.56M
STATE STREET CORP	31.5M	7.9%	$2.20B	+1.73M
VANGUARD PORTFOLIO MANAGEMENT LLC	31.2M	7.8%	$2.18B	−70.1K
GEODE CAPITAL MANAGEMENT, LLC	19.4M	4.9%	$1.36B	+550K
MORGAN STANLEY	19.1M	4.8%	$1.34B	+2.13M
Theleme Partners LLP	16.1M	4.0%	$1.13B	+18.7K

Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

MRNA insider trades
Insider	Trade	Shares	Price	Held after
Hoge StephenOfficer	exercised · Jun 15, 2026	16,110	$19.15	1,537,184
Hoge StephenOfficer	exercised · Jun 15, 2026	37,226	$19.15	1,521,074
Hoge StephenOfficer	sold · Jun 15, 2026	53,336	$51.37	1,483,848
Mock James MOfficer	withheld for tax · Jun 5, 2026	5,705	$51.59	65,687
Mock James MOfficer	exercised · Jun 5, 2026	11,798	—	71,392
Klinger Shannon ThymeOfficer	sold · Jun 4, 2026	3,471	$50.00	67,468
Klinger Shannon ThymeOfficer	exercised · Jun 4, 2026	3,471	$30.96	70,939
Klinger Shannon ThymeOfficer	withheld for tax · Jun 5, 2026	5,705	$51.59	73,561
Klinger Shannon ThymeOfficer	exercised · Jun 5, 2026	11,798	—	79,266
Hoge StephenOfficer	withheld for tax · Jun 1, 2026	4,488	$47.19	1,483,848

Corporate actions

exchange records

No corporate action on record for MRNA yet.

Price history

131 sessions on record · to Sep 30 · end of day

MRNA is +24.8% over 20 sessions against the S&P 500's +0.1%, 7.8% below its 52-week high, realised volatility 71% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions

Returns of the stock and S&P 500 over six windows, longest first
Window	From $	MRNA %	S&P 500 %	Difference pp
120 sessionssince Apr 9	$51.28	▲ +280%	▲ +12%	+260
60 sessionssince Jul 7	$79.77	▲ +140%	▲ +2.0%	+140
20 sessionssince Sep 1	$154.27	▲ +25%	▲ +0.11%	+25
5 sessionssince Sep 23	$182.12	▲ +5.7%	▼ −0.67%	+6.4
1 sessionsince Sep 29	$203.45	▼ −5.3%	▼ −0.21%	−5.1

Averages of the closeclose against each average

5-session average: $197.40close −2.4% from it
20-session average: $163.73close +18% from it
50-session average: $118.36close +63% from it

Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average

Average true range, 14: $147.0% of the close
Average day's range, 20: $147.0% of the close
Volume against 20 sessions: 1.37×20.6M vs 14.8M average

Volatility and co-movement with S&P 500annualised from daily returns

Realised volatility, 20: 71%≈ ±4.5% a session · moved more than that on 6 of 20
Realised volatility, 60: 230%≈ ±14% a session · moved more than that on 2 of 60
Beta to S&P 500, 60: 3.88moved with S&P 500 on 41 of 60 sessions

Up and down sessionscloses above and below the previous close

Last 20 sessions: 10 up · 10 downof 20
Last 60 sessions: 29 up · 31 downof 60
Best session, 250: ▲ +180%Aug 19
Worst session, 250: ▼ −24%Aug 20

Moderna, Inc. Common Stock is held by

4 headlines on MRNA

latest Sep 30, 2026 · links go to the publisher

Sep 30Prediction: Moderna Stock Will Soar 100% by 2030The Motley Fool Sep 30Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron EarningsThe Motley Fool Sep 30Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?Zacks Investment Research Sep 28Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?The Motley Fool

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 58% of reported volume on Sep 30, 2026, against 61% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume

MRNA daily short-sale volume
Session	Short volume	Reported volume	Short share
Sep 30, 2026	5.17M	8.96M	57.7%
Sep 29, 2026	4.36M	6.95M	62.8%
Sep 28, 2026	3.65M	5.91M	61.8%
Sep 25, 2026	4.4M	7.23M	60.8%
Sep 24, 2026	5.77M	8.9M	64.8%
Sep 23, 2026	5.56M	9.06M	61.3%
Sep 22, 2026	7.96M	12.7M	62.6%
Sep 21, 2026	6.36M	11.1M	57.4%
Sep 18, 2026	2.42M	3.87M	62.5%
Sep 17, 2026	5.74M	9.31M	61.7%

Filings

SEC EDGAR · newest first

MRNA SEC filings
Filed	Form	Report date
Sep 30, 2026	8-K	Sep 30, 2026
Sep 16, 2026	4	Sep 14, 2026
Sep 15, 2026	144	—
Sep 14, 2026	144	—
Sep 14, 2026	4	Sep 10, 2026
Sep 10, 2026	144	—
Sep 8, 2026	4	Sep 4, 2026
Sep 8, 2026	4	Sep 4, 2026
Sep 3, 2026	4	Sep 1, 2026
Sep 3, 2026	4	Sep 1, 2026
Sep 3, 2026	4	Sep 1, 2026
Sep 1, 2026	144	—
Sep 1, 2026	8-K	Aug 27, 2026
Aug 31, 2026	4	Aug 27, 2026
Aug 31, 2026	4	Aug 27, 2026
Aug 31, 2026	4	Aug 27, 2026
Aug 12, 2026	SCHEDULE 13G	—
Aug 7, 2026	4	Aug 5, 2026
Aug 6, 2026	SCHEDULE 13G/A	—
Aug 5, 2026	144	—
Jul 31, 2026	10-Q	Jun 30, 2026
Jul 31, 2026	8-K	Jul 31, 2026
Jul 24, 2026	SCHEDULE 13G/A	—
Jul 16, 2026	4	Jul 15, 2026
Jul 15, 2026	144	—

About Moderna, Inc. Common Stock

SEC and exchange records

Company: Moderna, Inc. Common Stock
Exchange: XNAS
Industry: Biological Products, (No Diagnostic Substances) · SEC standard industrial classification
SEC CIK: 1682852
Sessions on record: 131
Price source: End of day · delayed
Computed: 1 Oct, 10:39 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.